AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases

Science Translational Medicine

Volumn 8, Issue 368, 2016, Pages

  Yang, Zhenfan ^a   Guo, Qiuli ^a   Wang, Yingchun ^a   Chen, Kan ^a   Zhang, Lin ^a   Cheng, Ziqiang ^a   Xu, Yanping ^a   Yin, Xiaolu ^a   Bai, Yu ^a   Rabbie, Sarit ^a   Kim, Dong Wan ^b   Ahn, Myung Ju ^c   Yang, James Chih Hsin ^d   Zhang, Xiaolin ^a  

^a ASTRAZENECA   (United Kingdom)

^b Seoul National University Hospital   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZD 3759; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; PACLITAXEL; UNCLASSIFIED DRUG; AZD3759; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN METASTASIS; CANCER GROWTH; CASE REPORT; CENTRAL NERVOUS SYSTEM METASTASIS; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; EAST ASIAN; FEMALE; HUMAN; HUMAN CELL; LEPTOMENINGEAL METASTASIS; MIDDLE AGED; MOUSE; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT RESPONSE; TUMOR REGRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM TUMOR; DISEASE MODEL; DRUG EFFECTS; GENETICS; IC50; LUNG TUMOR; METABOLISM; METASTASIS; MUTATION; NUDE MOUSE; PATHOLOGY; SECONDARY; SPINAL CORD; TUMOR CELL LINE;

AGED; ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CENTRAL NERVOUS SYSTEM NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; MICE; MICE, NUDE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PIPERAZINES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SPINAL CORD;

EID: 85003467426     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aag0976     Document Type: Article

References (41)

1. D. Rangachari, N. Yamaguchi, P. A. VanderLaan, E. Folch, A. Mahadevan, S. R. Floyd, E. J. Uhlmann, E. T. Wong, S. E. Dahlberg, M. S. Huberman, D. B. Costa, Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer 88, 108-111 (2015).
2. N. W. Choong, S. Dietrich, T. Y. Seiwert, M. S. Tretiakova, V. Nallasura, G. C. Davies, S. Lipkowitz, A. N. Husain, R. Salgia, P. C. Ma, Gefitinib response of erlotinib-refractory lung cancer involving meninges-Role of EGFR mutation. Nat. Clin. Pract. Oncol. 3, 50-57 (2006).
3. J.-A. Palma, R. Fernandez-Torron, P. Esteve-Belloch, A. Fontes-Villalba, A. Hernandez, O. Fernandez-Hidalgo, J. Gallego Perez-Larraya, E. Martinez-Vila, Leptomeningeal carcinomatosis: Prognostic value of clinical, cerebrospinal fluid, and neuroimaging features. Clin. Neurol. Neurosurg. 115, 19-25 (2013).
4. Y. Fan, X. Xu, C. Xie, EGFR-TKI therapy for patients with brain metastases from non-small-cell lung cancer: A pooled analysis of published data. Onco. Targets Ther. 7, 2075-2084 (2014).
5. B.-C. Liao, J.-H. Lee, C.-C. Lin, Y.-F. Chen, C.-H. Chang, C.-C. Ho, J.-Y. Shih, C.-J. Yu, J. C.-H. Yang, Epidermal growth factor receptor tyrosine kinase inhibitors for non-small-cell lung cancer patients with leptomeningeal carcinomatosis. J. Thorac. Oncol. 10, 1754-1761 (2015).
6. S. Umemura, K. Tsubouchi, H. Yoshioka, K. Hotta, N. Takigawa, K. Fujiwara, N. Horita, Y. Segawa, N. Hamada, I. Takata, H. Yamane, H. Kamei, K. Kiura, M. Tanimoto, Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group. Lung Cancer 77, 134-139 (2012).
7. B. Borgelt, R. Gelber, M. Larson, F. Hendrickson, T. Griffin, R. Roth, Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: Final results of the first two studies by the Radiation Therapy Oncology Group. Int. J. Radiat. Oncol. Biol. Phys. 7, 1633-1638 (1981).
8. B. Borgelt, R. Gelber, S. Kramer, L. W. Brady, C. H. Chang, L. W. Davis, C. A. Perez, F. R. Hendrickson, The palliation of brain metastases: Final results of the first two studiesbythe Radiation Therapy Oncology Group. Int.J. Radiat. Oncol. Biol. Phys. 6, 1-9 (1980).
9. J. L. Clarke, W. Pao, N. Wu, V. A. Miller, A. B. Lassman, High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J. Neurooncol 99, 283-286 (2010).
10. D. M. Jackman, L. A. Cioffredi, L. Jacobs, F. Sharmeen, L. K. Morse, J. Lucca, S. R. Plotkin, P. J. Marcoux, M. S. Rabin, T. J. Lynch, B. E. Johnson, S. Kesari, A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer. Oncotarget 6, 4527-4536 (2015).
11. S. J. Park, H. T. Kim, D. H. Lee, K. P. Kim, S.-W. Kim, C. Suh, J. S. Lee, Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer 77, 556-560 (2012).
12. C. Wu, Y. L. Li, Z. M. Wang, Z. Li, T. X. Zhang, Z. Wei, Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer 57, 359-364 (2007).
13. T. Iuchi, M. Shingyoji, T. Sakaida, K. Hatano, O. Nagano, M. Itakura, H. Kageyama, S. Yokoi, Y. Hasegawa, K. Kawasaki, T. Iizasa, Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer 82, 282-287 (2013).
14. C. Grommes, G. R. Oxnard, M. G. Kris, V. A. Miller, W. Pao, A. I. Holodny, J. L. Clarke, A. B. Lassman, "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol. 13, 1364-1369 (2011).
15. F. Zagouri, T. N. Sergentanis, R. Bartsch, A. S. Berghoff, D. Chrysikos, E. de Azambuja, M.-A. Dimopoulos, M. Preusser, Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: A systematic review and pooled analysis. Breast Cancer Res. Treat. 139, 13-22 (2013).
16. Q. Zeng, J. Wang, Z. Cheng, K. Chen, P. Johnström, K. Varnäs, D. Y. Li, Z. F.Yang, X. Zhang, Discovery and evaluation of clinical candidate AZD3759, a potent, oral active, central nervous system-penetrant, epidermal growth factor receptor tyrosine kinase inhibitor. J. Med. Chem. 58, 8200-8215 (2015).
17. M. Hidalgo, L L. Siu, J. Nemunaitis, J. Rizzo, L A. Hammond, C. Takimoto, S. G. Eckhardt, A. Tolcher, C. D. Britten, L. Denis, K. Ferrante, D. D. Von Hoff, S. Silberman, E. K. Rowinsky, Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. 19, 3267-3279 (2001).
18. K. Chen, P. Martin, S. Rabbie, P. Johnström, Y. Wang, H. Y. Jiang, Z. F. Yang, Z. Q. Cheng, Prediction of human pharmacokinetics, efficacious dose and CNS penetration of AZD3759, an EGFR inhibitor for the treatment of NSCLC with brain and leptomeningeal metastasis. J. Thorac. Oncol. 10, S300 (2015).
19. M.-J. Ahn, D.-W. Kim, T. M. Kim, C.-C. Lin, J. Ratnayake, D.J. Carlile, X.Yin, Z.Yang, H.Jiang, J. C.-H. Yang, Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM). J. Clin. Oncol. 34, Abstract 9003 (2016).
20. D. Luo, X. Ye, Z. Hu, K. Peng, Y. Song, X. Yin, G. Zhu, Q. Ji, Y. Peng, EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases. Tumour Biol. 35, 2437-2444 (2014).
21. L. Cai, J.-f. Zhu, X.-w. Zhang, S.-x. Lin, X.-d. Su, P. Lin, K. Chen, L.-j. Zhang, A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer. J. Neurooncol 120, 423-430 (2014).
22. H. A. Yu, M. E. Arcila, N. Rekhtman, C. S. Sima, M. F. Zakowski, W. Pao, M. G. Kris, V. A. Miller, M. Ladanyi, G. J. Riely, Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 19, 2240-2247 (2013).
23. S. Sasaki, Y. Yoshioka, R. Ko, Y. Katsura, Y. Namba, T. Shukuya, K. Kido, S. Iwakami, S. Tominaga, K. Takahashi, Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure. Respir. Investig. 54, 14-19 (2016).
24. A. Hata, N. Katakami, H. Yoshioka, J. Takeshita, K. Tanaka, S. Nanjo, S. Fujita, R. Kaji, Y. Imai, K. Monden, T. Matsumoto, K. Nagata, K. Otsuka, R. Tachikawa, K. Tomii, K. Kunimasa, M. Iwasaku, A. Nishiyama, T. Ishida, Y. Nishimura, Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations. Cancer 119, 4325-4332 (2013).
25. J. Zhao, X. Ye, Y. Sun, Z. Yang, G. Zhu, M. Chen, W. Zhong, Y. Xu, L. Zhang, L. Li, Y. Xiao, M. Wang, EGFR mutation status in cerebrospinal fluid of NSCLC patients who developed leptomeningeal metastasis after EGFR-TKI treatment. J. Clin. Oncol. 32, Abstract 8081 (2014).
26. W. Lu, C. D. Bucana, A. J. Schroit, Pathogenesis and vascular integrity of breast cancer brain metastasis. Int. J. Cancer 120, 1023-1026 (2007).
27. K. S. Taskar, V. Rudraraju, R. K. Mittapalli, R. Samala, H. R. Thorsheim, J. Lockman, B. Gril, E. Hua, D. Palmieri, J. W. Polli, S. Castellino, S. D. Rubin, P. R. Lockman, P. S. Steeg, Q. R. Smith, Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm. Res. 29, 770-781 (2012).
28. P. S. Steeg, K. A. Camphausen, Q. R. Smith, Brain metastases as preventive and therapeutic targets. Nat. Rev. Cancer 11, 352-363 (2011).
29. A. F. Eichler, K. T. Kahle, D. L. Wang, V. A. Joshi, H. Willers, J. A. Engelman, T. J. Lynch, L. V. Sequist, EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol. 12, 1193-1199 (2010).
30. M. C. Chamberlain, P. Kormanik, Carcinoma meningitis secondary to non-small cell lung cancer: Combined modality therapy. Arch. Neurol. 55, 506-512 (1998).
31. L. Di, H. Rong, B. Feng, Demystifying brain penetration in central nervous system drug discovery. Miniperspective. J. Med. Chem. 56, 2-12 (2013).
32. J. Li, B. R. Davies, S. Han, M. Zhou, Y. Bai, J. Zhang, Y. Xu, L. Tang, H. Wang, Y. J. Liu, X. Yin, Q. Ji, D.-H. Yu, The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere. J. Transl. Med. 11, 241 (2013).
33. J. C. Reijneveld, M. J. B. Taphoorn, E. E. Voest, A simple mouse model for leptomeningeal metastases and repeated intrathecal therapy. J. Neurooncol 42, 137-142 (1999).
34. M. Schabet, U. Herrlinger, Animal models of leptomeningeal metastasis. J. Neurooncol 38, 199-205 (1998).
35. G. Schackert, I. J. Fidler, Development of in vivo models for studies of brain metastasis. Int. J. Cancer 41, 589-594 (1988).
36. G. Schackert, J. E. Price, C. D. Bucana, I. J. Fidler, Unique patterns of brain metastasis produced by different human carcinomas in athymic nude mice. Int. J. Cancer 44, 892-897 (1989).
37. S. Lal, M. Lacroix, P. Tofilon, G. N. Fuller, R. Sawaya, F. F. Lang, An implantable guide-screw system for brain tumor studies in small animals. J. Neurosurg. 92, 326-333 (2000).
38. E. M. Kemper, W. Leenders, B. Küsters, S. Lyons, T. Buckle, A. Heerschap, W. Boogerd, J. H. Beijnen, O. van Tellingen, Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies. Eur. J. Cancer 42, 3294-3303 (2006).
39. J. C. Kalvass, T. S. Maurer, G. M. Pollack, Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: Comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios. Drug Metab. Dispos. 35, 660-666 (2007).
40. Pathology Department, Animal and Plant Health Agency, Fixation, tissue processing, histology and immunohistochemistry procedures for diagnosis of animal TSE (BSE, Scrapie, Atypical Scrapie); http://www.protocolsonline.com/histology/ sample-preparation/paraffin-processing-of-tissue.
41. G. Zhu, X. Ye, Z. Dong, Y. C. Lu, Y. Sun, Y. Liu, R. McCormack, Y. Gu, X. Liu, Highly sensitive droplet digital PCR method for detection of EGFR-activating mutations in plasma cell-free DNA from patients with advanced non-small cell lung cancer. J. Mol. Diagn. 17, 265-272 (2015).